Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.
Highlights this week included:
Strattera (Atomoxetine) – US: Lilly’s patent for Strattera found invalid, Lilly appeals to Federal Circuit; wins short ban on generic Strattera (Patent Docs) (Law360) (GenericsWeb)
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
General
China – The basics on China pharma: Parts 1 & 2 (China Law Blog) (China Law Blog)
Mexico Patent Office excludes formulation patents from linkage gazette (Patent Docs)
UK: Medeva: still time to comment: Medeva v Comptroller General of Patents (SPC blog)
US: Chief Judge Rader’s views on patentable subject matter – Part I & 2: Prometheus Laboratories, Inc. v. Mayo Collaborative Services, Classen Immunotherapies, Inc. v. Biogen Idec, and Association for Molecular Pathology v. U.S. Patent and Trademark Office (Patent Docs) (Patent Docs)
US: PTO files amicus brief in Therasense case (Patent Docs) (Patent Docs)
US: AMP v. USPTO – Briefing schedule update (Patent Docs)
US: Patent expiration, pediatric exclusivity, and generic drug approval – Some interesting tensions between the FDC Act and patent law (FDA Law Blog)
Products
Androderm (Testosterone) – US: False marking complaint based on Watson’s marking of its Androderm products: Promote Innovation LLC v. Watson Pharma, Inc. et al. (Patent Docs)
Ablify (Aripiprazole) – Australia: Allowability of amendments under section 102 of the Patents Act (IP Whiteboard)
Boniva (Ibandronate) – US: Patent infringement complaint filed following a Paragraph IV certification: Hoffman-La Roche Inc. v. Orchid Chemicals & Pharmaceuticals Ltd. et al. (Patent Docs)
Clobex (Clobetasol propionate) – US: Patent infringement complaint filed following a Paragraph IV certification: Galderma Laboratories, L.P. et al. v. Perrigo Co. et al. (Patent Docs) (The IP Factor)
Dexpramipexole – US: Knopp Neurosciences deal shows how IP strategy can build value for licensing (IP Spotlight)
Dulera (Formoterol Fumarate and Mometasone Furoate) – India: Novartis loses Dulera patent in India (Patent Circle)
Evoxac (Cevimeline) – US: Daiichi, Apotex reach settlement in Evoxac patent suit (Patent Docs)
HPV detection kit – US: Arbitration award to Roche and Gen-Probe approved in HPV license suit with Qiagen (Patent Docs)
I-pill (Levonorgestrel) – India: Cipla knocks down key patent blocking i-pill (Patent Circle)
Lovenox (Enoxaparin) – US: Sanofi-Aventis sues FDA to stop generic blood-thinner drug (GenericsWeb)
Mirapex (Pramipexole) – US: Mylan generic Mirapex violates Boehringer’s patent (Patent Circle)
Neutrolin – US 7,696,182 for CorMedix of Bridgewater, NJ (IPBiz)
Nuvigil (Armodafinil) – US: Patent infringement complaint filed following a Paragraph IV certification: Cephalon, Inc. et al. v. Apotex Corp. et al. (Patent Docs)
OxyContin (Oxycodone) – Australia:Spirit Pharmaceutical’s OxyContin CR patent challenge threatens Mundipharma’s Australian market share (GenericsWeb)
Seroquel (Quetiapine) – US: Patent infringement complaint filed following a Paragraph IV certification: Astrazeneca Pharmaceuticals LP et al. v. Osmotica Pharmaceutical Corp (Patent Docs)
Seroquel (Quetiapine) – US: Patent infringement suit filed following Para IV certification: Astrazeneca Pharmaceuticals LP et al. v. Torrent Pharmaceuticals Ltd. et al. (Patent Docs)
Strattera (Atomoxetine) – US: Lilly’s patent for Strattera found invalid, Lilly appeals to Federal Circuit; wins short ban on generic Strattera (Patent Docs) (Law360) (GenericsWeb)
Tasigna (Nilotinib) – India: NCEs outside the scope of sec. 3(d), efficacy data not required (Patent Circle)
Uroxatral (Alfuzosin) – US: Aurobindo and Torrent lose Uroxatral patent lawsuit (Patent Circle)
Vytorin (Ezetimibe/Simvastatin) – US: Hatch-Waxman action on Vytorin: Schering v Impax (IPBiz) (GenericsWeb)